We are analyzing https://link.springer.com/article/10.1007/s00432-017-2513-4.

Title:
Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment | Journal of Cancer Research and Clinical Oncology
Description:
This study was attempted to investigate the safety and clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell therapy for treating stage III/IV pancreatic cancer, evaluate median progression-free survival (PFS), and overall survival (OS). Between March 2016 and February 2017, we enrolled 67 patients who met the enrollment criteria. According to the latest NCCN Guidelines, the patients were divided into stage III (35 patients, 16 patients received only irreversible electroporation (IRE) and 19 patients received IRE-NK: 8 patients underwent one course NK and 11 patients underwent ≥3 courses) and stage IV (32 patients, 14 patients received only IRE and 18 patients received IRE-NK: 8 patients underwent one course NK and 10 patients underwent ≥3 courses). The safety and short-term effects were evaluated first, then the median PFS, median OS, response rate (RR) and disease control rate (DCR) were assessed. Adverse events of all patients were limited to grades A and B, included local (mainly cough 12.7%, nausea and emesis 6.8%, pain of puncture point 25.3% and duodenum and gastric retention 5.9%) and systemic (mainly fatigue 21.5, fever 33.5%, and blood pressure intraoperative transient reduction 27.4% and white cell count reduction 22.6%) reactions, fever was most frequent. The serum amylase level at 24 h and 7 d after IRE was not significantly changed compared to those before IRE (P > 0.05). CA19-9 value was lower in IRE-NK group than in IRE at 1 month after treatment (P < 0.05). After a median follow-up of 7.9 months (3.8–12.1 months): in stage III group, median PFS was higher in IRE-NK group (9.1 months) than in IRE group (7.9 months, P = 0.0432), median OS was higher in IRE-NK (13.6 months) than in IRE (12.2 months; P = 0.0327), and median PFS was higher in who received multiple NK than single NK (9.9 vs. 8.2 months; P = 0.0387, respectively), median OS who received multiple NK was higher than single NK (13.7 vs. 12.1 months; P = 0.0451, respectively), the RR in IRE-NK (63.2%) was higher than in IRE (50.0%; P < 0.05); in stage IV group, median OS was higher in IRE-NK (10.2 months) than in IRE (9.1 months; P = 0.0367), the DCR in IRE-NK (66.7%) was higher than in IRE (42.9%; P < 0.05). Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy significantly increased median PFS and median OS in stage III pancreatic cancer and extended the median OS of stage IV pancreatic cancer. Multiple allogeneic natural killer cells infusion was associated with better prognosis to stage III pancreatic cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, cancer, article, google, scholar, cas, patients, pancreatic, cell, killer, irreversible, electroporation, cells, treatment, advanced, immunotherapy, lung, central, stage, median, natural, ire, months, locally, zhang, immunol, dois, oncol, surg, clinical, percutaneous, chen, niu, efficacy, irenk, cytokineinduced, liang, wang, safety, received, higher, combination, research, oncology, combined, allogeneic, study, survival, pfs, iii,

Topics {✒️}

cytokine-induced killer cells month download article/chapter small-cell lung cancer small-cell lung cancer cd158a + human nk cells kir/hla ligand incompatibility autologous dendritic cells nk cell-based immunotherapy her2-expressing breast cancer related subjects image-guided tumor ablation stage iii/iv postoperative adjuvant therapy killer cell immunoglobulin full article pdf fuda cancer hospital percutaneous irreversible electroporation unresectable pancreatic adenocarcinoma enhanced antitumor effects clinical oncology aims t4 pancreatic cancer metastatic pancreatic cancer significantly changed compared percutaneous cryoablation combined bone marrow transplantation pancreatic adenocarcinoma patients stage iv group advanced renal cancer privacy choices/manage cookies pancreatic cancer treatment stage iii group lizhi niu circulating tumor cells dendritic cells combining article lin metastatic hepatocellular cancer anti-pd-1 antibody received multiple nk adjuvant therapy check access instant access short-term effects tumor-specific cytotoxic hla-cw4 expression metastatic nasopharyngeal carcinoma ethics declarations conflict disease control rate pancreatic cancer european economic area serum amylase level

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment
         description:This study was attempted to investigate the safety and clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell therapy for treating stage III/IV pancreatic cancer, evaluate median progression-free survival (PFS), and overall survival (OS). Between March 2016 and February 2017, we enrolled 67 patients who met the enrollment criteria. According to the latest NCCN Guidelines, the patients were divided into stage III (35 patients, 16 patients received only irreversible electroporation (IRE) and 19 patients received IRE-NK: 8 patients underwent one course NK and 11 patients underwent ≥3 courses) and stage IV (32 patients, 14 patients received only IRE and 18 patients received IRE-NK: 8 patients underwent one course NK and 10 patients underwent ≥3 courses). The safety and short-term effects were evaluated first, then the median PFS, median OS, response rate (RR) and disease control rate (DCR) were assessed. Adverse events of all patients were limited to grades A and B, included local (mainly cough 12.7%, nausea and emesis 6.8%, pain of puncture point 25.3% and duodenum and gastric retention 5.9%) and systemic (mainly fatigue 21.5, fever 33.5%, and blood pressure intraoperative transient reduction 27.4% and white cell count reduction 22.6%) reactions, fever was most frequent. The serum amylase level at 24 h and 7 d after IRE was not significantly changed compared to those before IRE (P > 0.05). CA19-9 value was lower in IRE-NK group than in IRE at 1 month after treatment (P < 0.05). After a median follow-up of 7.9 months (3.8–12.1 months): in stage III group, median PFS was higher in IRE-NK group (9.1 months) than in IRE group (7.9 months, P = 0.0432), median OS was higher in IRE-NK (13.6 months) than in IRE (12.2 months; P = 0.0327), and median PFS was higher in who received multiple NK than single NK (9.9 vs. 8.2 months; P = 0.0387, respectively), median OS who received multiple NK was higher than single NK (13.7 vs. 12.1 months; P = 0.0451, respectively), the RR in IRE-NK (63.2%) was higher than in IRE (50.0%; P < 0.05); in stage IV group, median OS was higher in IRE-NK (10.2 months) than in IRE (9.1 months; P = 0.0367), the DCR in IRE-NK (66.7%) was higher than in IRE (42.9%; P < 0.05). Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy significantly increased median PFS and median OS in stage III pancreatic cancer and extended the median OS of stage IV pancreatic cancer. Multiple allogeneic natural killer cells infusion was associated with better prognosis to stage III pancreatic cancer.
         datePublished:2017-09-04T00:00:00Z
         dateModified:2017-09-04T00:00:00Z
         pageStart:2607
         pageEnd:2618
         sameAs:https://doi.org/10.1007/s00432-017-2513-4
         keywords:
            Percutaneous irreversible electroporation
            Allogeneic natural killer cell
            Pancreatic cancer
            Clinical efficacy
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig6_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:143
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mao Lin
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shuzhen Liang
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaohua Wang
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yinqing Liang
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mingjie Zhang
               affiliation:
                     name:Hank Bioengineering Co., Ltd
                     address:
                        name:Hank Bioengineering Co., Ltd, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jibing Chen
               url:http://orcid.org/0000-0001-8596-2126
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Lizhi Niu
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Jinan University School
                     address:
                        name:Department of Oncology, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kecheng Xu
               affiliation:
                     name:Jinan University School
                     address:
                        name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment
      description:This study was attempted to investigate the safety and clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell therapy for treating stage III/IV pancreatic cancer, evaluate median progression-free survival (PFS), and overall survival (OS). Between March 2016 and February 2017, we enrolled 67 patients who met the enrollment criteria. According to the latest NCCN Guidelines, the patients were divided into stage III (35 patients, 16 patients received only irreversible electroporation (IRE) and 19 patients received IRE-NK: 8 patients underwent one course NK and 11 patients underwent ≥3 courses) and stage IV (32 patients, 14 patients received only IRE and 18 patients received IRE-NK: 8 patients underwent one course NK and 10 patients underwent ≥3 courses). The safety and short-term effects were evaluated first, then the median PFS, median OS, response rate (RR) and disease control rate (DCR) were assessed. Adverse events of all patients were limited to grades A and B, included local (mainly cough 12.7%, nausea and emesis 6.8%, pain of puncture point 25.3% and duodenum and gastric retention 5.9%) and systemic (mainly fatigue 21.5, fever 33.5%, and blood pressure intraoperative transient reduction 27.4% and white cell count reduction 22.6%) reactions, fever was most frequent. The serum amylase level at 24 h and 7 d after IRE was not significantly changed compared to those before IRE (P > 0.05). CA19-9 value was lower in IRE-NK group than in IRE at 1 month after treatment (P < 0.05). After a median follow-up of 7.9 months (3.8–12.1 months): in stage III group, median PFS was higher in IRE-NK group (9.1 months) than in IRE group (7.9 months, P = 0.0432), median OS was higher in IRE-NK (13.6 months) than in IRE (12.2 months; P = 0.0327), and median PFS was higher in who received multiple NK than single NK (9.9 vs. 8.2 months; P = 0.0387, respectively), median OS who received multiple NK was higher than single NK (13.7 vs. 12.1 months; P = 0.0451, respectively), the RR in IRE-NK (63.2%) was higher than in IRE (50.0%; P < 0.05); in stage IV group, median OS was higher in IRE-NK (10.2 months) than in IRE (9.1 months; P = 0.0367), the DCR in IRE-NK (66.7%) was higher than in IRE (42.9%; P < 0.05). Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy significantly increased median PFS and median OS in stage III pancreatic cancer and extended the median OS of stage IV pancreatic cancer. Multiple allogeneic natural killer cells infusion was associated with better prognosis to stage III pancreatic cancer.
      datePublished:2017-09-04T00:00:00Z
      dateModified:2017-09-04T00:00:00Z
      pageStart:2607
      pageEnd:2618
      sameAs:https://doi.org/10.1007/s00432-017-2513-4
      keywords:
         Percutaneous irreversible electroporation
         Allogeneic natural killer cell
         Pancreatic cancer
         Clinical efficacy
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-017-2513-4/MediaObjects/432_2017_2513_Fig6_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:143
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mao Lin
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shuzhen Liang
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaohua Wang
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yinqing Liang
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mingjie Zhang
            affiliation:
                  name:Hank Bioengineering Co., Ltd
                  address:
                     name:Hank Bioengineering Co., Ltd, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jibing Chen
            url:http://orcid.org/0000-0001-8596-2126
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lizhi Niu
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Jinan University School
                  address:
                     name:Department of Oncology, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kecheng Xu
            affiliation:
                  name:Jinan University School
                  address:
                     name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:143
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Hank Bioengineering Co., Ltd
      address:
         name:Hank Bioengineering Co., Ltd, Shenzhen, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Oncology, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Jinan University School
      address:
         name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mao Lin
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Shuzhen Liang
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Xiaohua Wang
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Yinqing Liang
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Mingjie Zhang
      affiliation:
            name:Hank Bioengineering Co., Ltd
            address:
               name:Hank Bioengineering Co., Ltd, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Jibing Chen
      url:http://orcid.org/0000-0001-8596-2126
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lizhi Niu
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Jinan University School
            address:
               name:Department of Oncology, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kecheng Xu
      affiliation:
            name:Jinan University School
            address:
               name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Hank Bioengineering Co., Ltd, Shenzhen, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China
      name:Department of Oncology, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(258)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.52s.

LINK . SPRINGER . COM {}